FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149392634> ?p ?o ?g. }

• W2149392634 endingPage "70" @default.
• W2149392634 startingPage "1563" @default.
• W2149392634 abstract "We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficiency (SCID) mouse using both the drug-sensitive 8226/S human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. As demonstrated previously, the SCID mouse is well suited as a model for myeloma because: (a) human SCID xenografts are readily attained; (b) human myeloma xenografts are readily detected by their immunoglobulin secretion; and (c) differential therapy effects in drug-sensitive versus drug-resistant cell lines are readily demonstrable by monitoring mouse urinary human immunoglobulin output. In the current study, we have utilized this model to evaluate the in vivo efficacy of chemomodulators of P-glycoprotein-related multidrug resistance. In our initial experiments, doxorubicin alone was effective in treating the 8226/S human myeloma xenografts but had no effect on the drug-resistant 8226/C1N xenografts, in the absence of the chemosensitizing agent verapamil. In subsequent experiments, the combination of verapamil and doxorubicin resulted in both a decrease in human lambda light chain urinary excretion and an increase in survival of those animals bearing the 8226/C1N tumor. The median survival time of animals injected with 8226/C1N cells and subsequently treated with doxorubicin was 48.6 +/- 7 days, which compared to a survival of 89.6 +/- 18 days in animals receiving the 8226/S cell line and treated with doxorubicin alone (P < 0.001). When verapamil was added to the treatment regimen of those animals bearing the 8226/C1N xenografts, there was a 179% increase in their life span (P < 0.001), which corresponded with the observed decreased light chain in the urine. In animals receiving multiple courses of chemotherapy, an attenuated response to verapamil and doxorubicin was observed, in a manner analogous to the clinical setting of human drug-resistant myeloma escape from chemosensitivity. The SCID human myeloma xenograft model thus offers a means of evaluating the in vivo efficacy and potential toxicities of new therapeutic approaches directed against P-glycoprotein in multidrug-resistant human myeloma." @default.
• W2149392634 created "2016-06-24" @default.
• W2149392634 creator A5054731742 @default.
• W2149392634 creator A5056492087 @default.
• W2149392634 creator A5058560274 @default.
• W2149392634 creator A5064039283 @default.
• W2149392634 creator A5071127912 @default.
• W2149392634 creator A5072898775 @default.
• W2149392634 date "1995-12-01" @default.
• W2149392634 modified "2023-09-27" @default.
• W2149392634 title "Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts." @default.
• W2149392634 cites W1754065147 @default.
• W2149392634 cites W1776168062 @default.
• W2149392634 cites W1958840615 @default.
• W2149392634 cites W1964470226 @default.
• W2149392634 cites W196876215 @default.
• W2149392634 cites W2027446242 @default.
• W2149392634 cites W2049520769 @default.
• W2149392634 cites W2056409361 @default.
• W2149392634 cites W2078877172 @default.
• W2149392634 cites W2143126774 @default.
• W2149392634 cites W2161983472 @default.
• W2149392634 cites W2165579893 @default.
• W2149392634 cites W2170255900 @default.
• W2149392634 cites W2210404574 @default.
• W2149392634 cites W2301279425 @default.
• W2149392634 cites W2397577365 @default.
• W2149392634 cites W2402432724 @default.
• W2149392634 cites W2404356933 @default.
• W2149392634 cites W2413215251 @default.
• W2149392634 cites W47498184 @default.
• W2149392634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9815957" @default.
• W2149392634 hasPublicationYear "1995" @default.
• W2149392634 type Work @default.
• W2149392634 sameAs 2149392634 @default.
• W2149392634 citedByCount "1" @default.
• W2149392634 crossrefType "journal-article" @default.
• W2149392634 hasAuthorship W2149392634A5054731742 @default.
• W2149392634 hasAuthorship W2149392634A5056492087 @default.
• W2149392634 hasAuthorship W2149392634A5058560274 @default.
• W2149392634 hasAuthorship W2149392634A5064039283 @default.
• W2149392634 hasAuthorship W2149392634A5071127912 @default.
• W2149392634 hasAuthorship W2149392634A5072898775 @default.
• W2149392634 hasConcept C114851261 @default.
• W2149392634 hasConcept C126322002 @default.
• W2149392634 hasConcept C133936738 @default.
• W2149392634 hasConcept C150903083 @default.
• W2149392634 hasConcept C159654299 @default.
• W2149392634 hasConcept C203014093 @default.
• W2149392634 hasConcept C207001950 @default.
• W2149392634 hasConcept C2776364478 @default.
• W2149392634 hasConcept C2776694085 @default.
• W2149392634 hasConcept C2777022698 @default.
• W2149392634 hasConcept C2778707650 @default.
• W2149392634 hasConcept C2779468541 @default.
• W2149392634 hasConcept C2781303535 @default.
• W2149392634 hasConcept C502942594 @default.
• W2149392634 hasConcept C519063684 @default.
• W2149392634 hasConcept C71924100 @default.
• W2149392634 hasConcept C86803240 @default.
• W2149392634 hasConcept C89423630 @default.
• W2149392634 hasConcept C98274493 @default.
• W2149392634 hasConceptScore W2149392634C114851261 @default.
• W2149392634 hasConceptScore W2149392634C126322002 @default.
• W2149392634 hasConceptScore W2149392634C133936738 @default.
• W2149392634 hasConceptScore W2149392634C150903083 @default.
• W2149392634 hasConceptScore W2149392634C159654299 @default.
• W2149392634 hasConceptScore W2149392634C203014093 @default.
• W2149392634 hasConceptScore W2149392634C207001950 @default.
• W2149392634 hasConceptScore W2149392634C2776364478 @default.
• W2149392634 hasConceptScore W2149392634C2776694085 @default.
• W2149392634 hasConceptScore W2149392634C2777022698 @default.
• W2149392634 hasConceptScore W2149392634C2778707650 @default.
• W2149392634 hasConceptScore W2149392634C2779468541 @default.
• W2149392634 hasConceptScore W2149392634C2781303535 @default.
• W2149392634 hasConceptScore W2149392634C502942594 @default.
• W2149392634 hasConceptScore W2149392634C519063684 @default.
• W2149392634 hasConceptScore W2149392634C71924100 @default.
• W2149392634 hasConceptScore W2149392634C86803240 @default.
• W2149392634 hasConceptScore W2149392634C89423630 @default.
• W2149392634 hasConceptScore W2149392634C98274493 @default.
• W2149392634 hasIssue "12" @default.
• W2149392634 hasLocation W21493926341 @default.
• W2149392634 hasOpenAccess W2149392634 @default.
• W2149392634 hasPrimaryLocation W21493926341 @default.
• W2149392634 hasRelatedWork W2023759982 @default.
• W2149392634 hasRelatedWork W2029852535 @default.
• W2149392634 hasRelatedWork W2129571992 @default.
• W2149392634 hasRelatedWork W2139274035 @default.
• W2149392634 hasRelatedWork W2149392634 @default.
• W2149392634 hasRelatedWork W2170173738 @default.
• W2149392634 hasRelatedWork W2281118821 @default.
• W2149392634 hasRelatedWork W2397490390 @default.
• W2149392634 hasRelatedWork W2434473292 @default.
• W2149392634 hasRelatedWork W2740003291 @default.
• W2149392634 hasVolume "1" @default.
• W2149392634 isParatext "false" @default.
• W2149392634 isRetracted "false" @default.

• next